Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b RNA-based COVID-19 vaccine candidates in vaccine-experienced adults
NCT05472038Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BNT162b5 in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Jul 2022; status: completed.
02
Drugs
BNT162b5
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05472038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472038.